Pharmaceutical Benefits Scheme (PBS) prescription—therapeutic group, code N

Exported from METEOR (AIHW's Metadata Online Registry)		
© Australian Institute of Health and Welfare 2024		
This product, excluding the AlHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third		

This product, excluding the AlHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AlHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at https://creativecommons.org/licenses/by/4.0/.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Pharmaceutical Benefits Scheme (PBS) prescription—therapeutic group, code N

Identifying and definitional attributes

Metadata item type: Data Element

Short name: Therapeutic group

METEOR identifier: 605587

Registration status: Commonwealth Department of Health, Retired 19/10/2023

Definition: A narrowly defined group of drugs listed in the Schedule of Pharmaceutical

Benefits that are of similar safety and efficacy and provide similar health outcomes,

as represented by a code.

Context: Therapeutic groups are defined for the purpose of comparative pricing. The

government subsidises all drugs within a therapeutic group up to the level of the lowest priced drug. Any difference between the subsidised price and the price of the drug used by the patient is called the 'therapeutic group premium' and is paid

by the patient.

Data Element Concept: Pharmaceutical Benefits Scheme (PBS) prescription—therapeutic group

Value Domain: <u>Therapeutic group code N</u>

Value domain attributes

Representational attributes

Representation class: Code

Data type: Number

Format: N

Maximum character length: 1

	Value	Meaning
Permissible values:	1	ACE inhibitor group
	2	ATRA group
	4	H2RA group
	5	PPI group
	7	Statins-HP group
	8	Venlafaxine group

Supplementary values: 0 Item does not belong to a therapeutic group

Collection and usage attributes

Guide for use:

Due to the number of changes to the lists of drugs included in the various therapeutic groups, this value domain is only suitable for use in relation to data for part or all of the 2013-14 financial year.

The Permissible values in this value domain equate to Part numbers in the relevant Determination describing each therapeutic group and the drugs included in each therapeutic group, i.e. the *National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2010 (PB 1 of 2010)* (Cwth).

CODE 1 Angiotensin converting enzyme (ACE) inhibitor group

This group includes the following listed drugs:

Fosinopril

NOTE: This therapeutic group was removed from the therapeutic groups listed in the Determination by amendment PB 47 of 2013, effective from 1 August 2013.

CODE 2 Angiotensin II receptor antagonist (ATRA) group

This group includes the following listed drugs:

 Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan

CODE 4 H2 receptor antagonist (H2RA) group

This group includes the following listed drugs:

Nizatidine

CODE 5 Proton pump inhibitor (PPI) group

This group includes the following listed drugs:

• Esomeprazole, Rabeprazole

NOTE: Rabeprazole was removed from this therapeutic group, as listed in the Determination, by amendment PB 23 of 2014, effective from 1 April 2014.

CODE 7 Statins-HP group

This group includes the following listed drugs:

Atorvastatin, Rosuvastatin

NOTE: Atorvastatin was removed from this therapeutic group, as listed in the Determination, by amendment PB 77 of 2013, effective from 1 December 2013.

CODE 8 Venlafaxine group

This group includes the following listed drugs:

• Desvenlafaxine, Venlafaxine

NOTE: Venlafaxine was removed from this therapeutic group, as listed in the Determination, by amendment PB 77 of 2013, effective from 1 December 2013.

Comments:

This value domain retains the relevant permissible values, i.e. Part numbers from within the Determination, from previous versions to ensure consistency across versions.

Source and reference attributes

Submitting organisation: Department of Health

Reference documents:

Office of Parliamentary Counsel, ComLaw website 2013. National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2010 (PB 1 of 2010), including amendments up to PB 6 and 7 of 2013. Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015, https://www.comlaw.gov.au/Details/F2013C00269

Office of Parliamentary Counsel, ComLaw website 2013. National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2013 (No. 3) (PB No. 47 2013). Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015,

https://www.comlaw.gov.au/Details/F2013L01455

Office of Parliamentary Counsel, ComLaw website 2013. National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2010 (PB 1 of 2010), including amendments up to PB 47 of 2013. Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015, https://www.comlaw.gov.au/Details/F2013C00559

Office of Parliamentary Counsel, ComLaw website 2013. National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2013 (No. 4) (PB No. 77 2013). Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015,

https://www.comlaw.gov.au/Details/F2013L02010

Office of Parliamentary Counsel, ComLaw website 2013. National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2010 (PB 1 of 2010), including amendments up to PB 77 of 2013. Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015, https://www.comlaw.gov.au/Details/F2013C00954

Office of Parliamentary Counsel, ComLaw website 2014. National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2014 (No. 1) (PB No. 23 2014). Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015.

https://www.comlaw.gov.au/Details/F2014L00359

Office of Parliamentary Counsel, ComLaw website 2014. National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2010 (PB 1 of 2010), including amendments up to PB 23 of 2014. Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015, https://www.comlaw.gov.au/Details/F2014C00292

Data element attributes

Collection and usage attributes

Guide for use: Drugs listed within a therapeutic group are therapeutically interchangeable with

other drugs in the same group.

Source and reference attributes

Submitting organisation: Department of Health

Relational attributes

Specifications:

Implementation in Data Set Pharmaceutical Benefits Scheme (PBS) state/territory data extract 2013-14

Commonwealth Department of Health, Retired 19/10/2023

Implementation start date: 01/07/2013 Implementation end date: 30/06/2014

DSS specific information:

Variable name = THRPTC_GRP_CD